This observational pilot prospective study will evaluate a new method for remote monitoring of corrected QT measurement using an artificial intelligence (AI)-based solution and ECG data collected via smartwatches (AI-QTc), in patients ambulatory treated with the HC-AZ combination, at the early stage of COVID-19 infection, at a tertiary hospital center. Daily ECGs will be performed via the smartwatches. AI-QTc will be compared to standard manual QTc reviewed by cardiologist. Correlation and agreement between measures will be assessed.
Inclusion Criteria:
- Patient over 18 years old
- SARS-COV-2 confirmed infection by positive nasopharyngual PCR
- Prescription of association hydroxychloroquine and azythromycine for COVI-19 therapy
- Patient's smartphone able to download the smartwatches application
Exclusion Criteria:
- Presence of a pacemaker
- Pregnant or breastfeeding females
- Refusal to participate
- Incapacity
- Adult under legal protection (trusteeship, guardianship)
Assistance Publique Hôpitaux de Marseille
Marseille, France